コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ] control, cholesterol level management, and smoking cessation).
2 ressure control, cholesterol management, and smoking cessation).
3 n-hospital following ACS, is efficacious for smoking cessation.
4 tential methods and resources to assist with smoking cessation.
5 n reducing child TSE and increasing parental smoking cessation.
6 The primary endpoint was cigarette smoking cessation.
7 keletal muscle are most likely reversible by smoking cessation.
8 ddiction, smoking, cigarettes, nicotine, and smoking cessation.
9 four incentive programs or to usual care for smoking cessation.
10 esponse to nicotine patch or varenicline for smoking cessation.
11 cline is an effective pharmacotherapy to aid smoking cessation.
12 d by clinical guidelines recommending abrupt smoking cessation.
13 lution of epigenetic changes with time since smoking cessation.
14 g-related brain changes are reversible after smoking cessation.
15 [CI, 2.02 to 2.55]) were also effective for smoking cessation.
16 ly methylated, even more than 35 years after smoking cessation.
17 own regarding the underlying neurobiology of smoking cessation.
18 enicline's efficacy as a pharmacotherapy for smoking cessation.
19 rly and sustained antiretroviral therapy and smoking cessation.
20 ring pregnancy is considered ineffective for smoking cessation.
21 g negative effect modification by time since smoking cessation.
22 s inhaler) were most effective for achieving smoking cessation.
23 rettes per day, and a willingness to attempt smoking cessation.
24 ic obstructive pulmonary disease, even after smoking cessation.
25 o definitively establish their potential for smoking cessation.
26 risk, similar to the benefit associated with smoking cessation.
27 of the PFC and insula bilaterally can induce smoking cessation.
28 sk of EAC, although some evidence exists for smoking cessation.
29 nic cigarettes (e-cigarettes) may facilitate smoking cessation.
30 fect of motivational interviewing on nurses' smoking cessation.
31 ontributing to its ability to aid in tobacco smoking cessation.
32 vidence in support of the health benefits of smoking cessation.
33 determine the role of combination therapy in smoking cessation.
34 t of pretreatment upregulation of nAChRs and smoking cessation.
35 ks of smoking, and counseling patients about smoking cessation.
36 tic shared by pharmacologic agents promoting smoking cessation.
37 dies are needed to explore rTMS as an aid to smoking cessation.
38 s), diabetes risk was not elevated following smoking cessation.
39 or investigation of therapeutic potential in smoking cessation.
40 low-density lipoprotein >100 mg/dL, and (6) smoking cessation.
41 ) of alpha7 receptors, JNJ-39393406, may aid smoking cessation.
42 tion if nurses are to be effective agents of smoking cessation.
43 her be studied in a larger clinical trial of smoking cessation.
44 ation and airway wall remodeling, even after smoking cessation.
45 reduction, increasing physical activity, and smoking cessation.
46 altered methylation, with attenuation, after smoking cessation.
47 cial incentives increased long-term rates of smoking cessation.
48 the previous development of varenicline for smoking cessation.
49 hat, at many loci, persists many years after smoking cessation.
50 D prevention and tobacco cessation drugs for smoking cessation.
52 o implementing effective measures to promote smoking cessation, a crucial element of both the Framewo
57 ttempts to reduce the risk of IF may include smoking cessation, aggressive control of hyperglycemia,
60 use of preventable diseases; thus, effective smoking cessation aids are crucial for reducing the prev
65 tinic acetylcholine receptor and is used for smoking cessation, almost doubles the chances of quittin
66 iation between e-cigarette use and cigarette smoking cessation among adult cigarette smokers, irrespe
68 re examined for association with prospective smoking cessation among smokers of European ancestry tre
70 armacotherapy interventions improve rates of smoking cessation among the general adult population, al
71 ed programmes of screening, vaccination, and smoking cessation, among other prevention strategies.
73 we examined associations between duration of smoking cessation and colorectal cancer risk according t
74 ated into most public health guidelines (eg, smoking cessation and control of bodyweight and blood pr
77 e has been approved in the United States for smoking cessation and cytisine is used in Eastern Europe
78 orporating both lifestyle changes, including smoking cessation and exercise, as well as optimal medic
80 ote health initiatives in areas ranging from smoking cessation and healthy diet to organ transplantat
81 of reduced-nicotine cigarettes to facilitate smoking cessation and on policy regarding regulation of
84 e findings emphasize the importance of early smoking cessation and preferably the avoidance of smokin
85 ing may be an effective way to increase male smoking cessation and reduce mother and newborn SHS expo
86 characterized by a negative mood state upon smoking cessation and relapse after periods of abstinenc
87 interventions increased adherence to ART and smoking cessation and should be considered for inclusion
88 he association between cigarette smoking and smoking cessation and the prevalence and incidence of to
89 the efficacy and safety of e-cigarettes for smoking cessation and to consider issues relevant to the
92 Psilocybin is being tested for alcoholism, smoking cessation, and in patients with advanced cancer
93 ypical of never smokers within decades after smoking cessation, and sites remaining differentially me
94 l, lipid control, diabetic glycemic control, smoking cessation, and target body mass index by engagin
95 gnificantly increased within 3-9 years since smoking cessation, and the significant association persi
96 he dynamics of methylation changes following smoking cessation are driven by a differential and site-
101 ctiveness of TWH interventions for improving smoking cessation, as measured by self-reported 7-day ab
102 free medication resulted in higher rates of smoking cessation at 6 months compared with a standard r
106 se for the initialization and maintenance of smoking cessation because of their ability to block the
107 ic control and preventive measures including smoking cessation, blood pressure control, and lipid man
108 oking-related CMH usually resolves following smoking cessation but the longer its duration the greate
109 ffers an intriguing therapeutic approach for smoking cessation, but a reliably effective and immunolo
110 perceived stress may comprise a barrier for smoking cessation, but little is known about the associa
116 ACEI/ARB (OR: 2.6; 95% CI: 1.8 to 3.9), and smoking cessation counseling (OR: 4.4; 95% CI: 2.0 to 9.
119 atients were less likely to receive statins, smoking cessation counseling, and defect-free care.
120 effectiveness of a medical (walking program, smoking cessation counseling, and medications) vs revasc
121 ho did not receive face-to-face or telephone smoking cessation counseling, large financial incentives
124 -analysis of 9 trials that measured parental smoking cessation demonstrated no overall intervention e
126 otine has practical applications relating to smoking cessation devices and alternative nicotine produ
129 enuation was largely due to a higher rate of smoking cessation during the study period among men with
130 tcome expectancies support the importance of smoking cessation efforts in patients with orofacial pai
133 This issue provides a clinical overview of smoking cessation, focusing on health consequences of sm
137 therapy as an adjunct to diet, exercise, and smoking cessation has proven highly effective in reducin
139 ealth successes, including HIV treatment and smoking cessation, have contributed to declining prematu
141 erted effort should be made toward promoting smoking cessation in all patients scheduled for elective
144 ce for a neurochemical target, which may aid smoking cessation in highly cue-reactive individuals.
145 ough which nicotinic compounds may be aiding smoking cessation in individuals experiencing withdrawal
146 dentify and overcome barriers to integrating smoking cessation in lung cancer screening settings.
147 SHS is an important factor associated with smoking cessation in lung cancer survivors of all stages
153 nAChR PAM compound for possible efficacy in smoking cessation, in smokers with or without schizophre
154 actors associated with greater benefits from smoking cessation included younger age, higher initial C
158 2.6%], P = .01 for interaction term), and in smoking cessation interventions (12.4% vs 7.7%, differen
159 to consider in the design and development of smoking cessation interventions and tobacco regulation.
160 antipsychotic adverse effect monitoring, and smoking cessation interventions are needed from the earl
162 and safety of pharmacological and behavioral smoking cessation interventions in CVD patients via a me
164 l of nurses' engagement with the delivery of smoking cessation interventions requires attention if nu
165 g cancer screening setting of evidence-based smoking cessation interventions shown to be effective in
166 unding the integration and implementation of smoking cessation interventions with LDCT lung cancer sc
167 ized tools for use in conducting research on smoking cessation interventions within the LDCT lung can
168 The best approach for integrating effective smoking cessation interventions within this setting is u
174 China, an immediate increase in the pace of smoking cessation is essential to avoid a rising burden
176 ssion of pancreatitis and reduce recurrence; smoking cessation is the most effective strategy to redu
178 tly related to varenicline use, or caused by smoking cessation itself or reflects depression and suic
179 assess efficacy were biochemically verified smoking cessation, mean cigarettes smoked, stages of cha
180 nse telephone calls and their choice of free smoking cessation medication (any type approved by the U
181 provide a promising target in the search for smoking cessation medication with novel mechanisms of ac
184 sed about the neuropsychiatric safety of the smoking cessation medications varenicline and bupropion.
185 st whether 4-year change in weight following smoking cessation modified the association between smoki
186 based programmes that promote weight loss or smoking cessation need to be more accessible for these p
189 ral modification, such as dietary changes or smoking cessation, not only reduces stroke risk, but als
190 Our results provide a new paradigm for how smoking cessation occurs and suggest how more effective
191 emiology data suggest a protective effect of smoking cessation on a DNA methylation-related carcinoge
193 stematic review is to evaluate the effect of smoking cessation on periodontitis progression and respo
194 for cataract development, but the effect of smoking cessation on the risk of cataract is uncertain.
195 stolic blood pressure, glycemic control, and smoking cessation, only 18% of the COURAGE diabetes subg
198 ake of targeted preventive services, such as smoking cessation or relevant immunizations; and the pos
203 Secondary outcomes of interest were parental smoking cessation, parental smoking reduction, and mater
204 controlled trials evaluating the efficacy of smoking cessation pharmacotherapies and behavioral thera
205 andomized to one of three 12-week open-label smoking cessation pharmacotherapy groups: (1) nicotine p
208 udies were included if they reported nurses' smoking cessation practices in relation to their persona
209 Proportions of nurses' smoking status and smoking cessation practices were pooled across studies u
217 orporates systematic screening practice with smoking cessation programs and offers opportunities for
218 hould be a key consideration when developing smoking cessation programs for patients with lung cancer
219 and clinical trials evaluating the effect of smoking-cessation programs, alone or in combination with
220 and autonomic function may be restored after smoking cessation, providing further evidence in support
221 that validate a previously established v1.0 smoking cessation quit success genotype score and descri
222 The purpose of this study was to examine smoking cessation rates among smokers with AMI to determ
223 ompared with placebo significantly increased smoking cessation rates at the end of treatment, and als
224 with a clinically significant difference in smoking cessation rates compared with abrupt cessation.
225 arge financial incentives improved long-term smoking cessation rates in low-income smokers, in a gene
226 large financial incentives enhance long-term smoking cessation rates outside clinical or workplace se
232 line exerts a robust and favorable effect on smoking cessation relative to placebo and may have a fav
235 was comparable, except for a higher rate of smoking cessation screening and intervention (adjusted r
237 Based on the limited available evidence, smoking cessation seems to have a positive influence on
241 oke but typically do not access conventional smoking cessation services, contributing to widening hea
243 moking but did cause a temporary doubling of smoking cessation shortly after randomisation during pre
244 % of MIs among HIV-infected individuals, and smoking cessation should be a primary focus in modern HI
245 on the benefits and harms of screening, and smoking cessation should be offered to all current smoke
246 tified in the postoperative period, although smoking cessation should be strongly encouraged given th
250 is a pilot randomised controlled trial of a smoking cessation strategy designed specifically for peo
252 Participants engaged well with the bespoke smoking cessation strategy, but no individuals assigned
253 net effect of radiotherapy on mortality, but smoking cessation substantially reduces radiotherapy ris
254 ice and an association between NRG3 SNPs and smoking cessation success was detected in a clinical tri
255 (a) we have identified genetic predictors of smoking cessation success, (b) genetic influences on qui
257 hronic inflammation that persists even after smoking cessation, suggesting that a failure to resolve
258 genes remained elevated up to 30 years after smoking cessation, suggesting that the molecular consequ
260 se that smoke-free psychiatric units provide smoking cessation support on patient admission to the ho
262 ed the evidence on interventions for tobacco smoking cessation that are relevant to primary care (beh
263 nternet-based intervention (StopAdvisor) for smoking cessation that was designed with particular atte
264 erved earlier, but more than 2 decades after smoking cessation, the risk of cataract extraction did n
266 s entailed rewards of approximately $800 for smoking cessation; the others entailed refundable deposi
270 there is historical and renewed concern that smoking cessation therapies may increase the risk of car
272 We aimed to examine whether the 3 licensed smoking cessation therapies-nicotine replacement therapy
273 the safety and efficacy of e-cigarettes as a smoking cessation therapy, available evidence showed no
274 evention efforts should continue to focus on smoking cessation, these prospective findings support th
279 thdrawal may inform the development of novel smoking cessation treatments and reduce the harm caused
280 izers may benefit from adjunctive behavioral smoking cessation treatments, such as cue exposure thera
282 f nicotine replacement therapy (NRT) use and smoking cessation using data from the Ontario Tobacco Su
283 of smoking-induced epigenetic changes after smoking cessation, using genome-wide methylation profile
289 15 cigarettes or less per day, the effect of smoking cessation was observed earlier, but more than 2
291 mood and behavior independent of smoking and smoking cessation, we assessed the effects of vareniclin
293 to receive either booklets plus access to a smoking cessation website (control group, n = 404), or t
295 Changes in lipid expression after 2-month smoking cessation were investigated in smokers with and
299 Prospective evidence of the associations of smoking cessation with chronic obstructive pulmonary dis
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。